Progress in Neurotherapeutics and Neuropsychopharmacology

Volume 1, 2006
Herausgeber: Cummings, Jeffrey L.

• Broschiertes Buch

Produktbeschreibung

Published annually, volumes in this series provide readers with updates of clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 184
• Erscheinungstermin: 11. Juli 2012
• Englisch
• Abmessung: 244mm x 170mm x 10mm
• Gewicht: 329g
• ISBN-13: 9781107405875
• ISBN-10: 1107405874
• Artikelnr.: 35895738

Inhaltsangabe

Preface J. L. Cummings; Introduction to neurotherapeutics and
neuropharmacology J. L. Cummings; 1. Rivastigmine in the treatment of
dementia associated with Parkinson's disease: a randomized, double-blind,
placebo-controlled study S. Tekin and R. Lane; 2. Modafinil for the
treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M.
Clanet; 3. Radiotherapy with concurrent and adjuvant temozolomide: a new
standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff
and R Stupp; 4. Treating migraine attacks ASAP: concept and methodological
issues N. J. Wiendels and M. D. Ferrari; 5. Early phase trials of
minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H.
Moore and R. G. Miller; 6. Creatine as a potential treatment for
amyotrophic lateral sclerosis J. M. Shefner; 7. AVP-923 as a novel
treatment for pseudobulbar affect ALS L. E. Pope; 8. Liquid fluoxetine vs.
placebo for repetitive behaviors in childhood autism E. Hollander, E.
Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman; 9.
Testing multiple novel mechanisms for treating schizophrenia in a single
trial H. Y. Meltzer; 10. Selegiline in the treatment of negative symptoms
of schizophrenia A. Lin and A. Bodkin; 11. Analysis of the cognitive
enhancing effects of modafinil in schizophrenia D. C. Turner and B. J.
Sahakian; 12. Efficacy and tolerability of ziprasidone and olanzapine in
acutely ill inpatient with schizophrenia or schizoaffective disorder:
results of a double-blind, 6-week study, with a 6-month, double-blind,
continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang.